# Study Evaluating Safety, Tolerability and Pharmacokinetics of EYP001a in Healthy Male Subjects

> **NCT03110276** · PHASE1 · COMPLETED · sponsor: **Enyo Pharma** · enrollment: 80 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** EYP001a
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03110276
- **Lead sponsor:** Enyo Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08
- **Primary completion:** 2017-03
- **Final completion:** 2017-03
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2017-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03110276

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03110276, "Study Evaluating Safety, Tolerability and Pharmacokinetics of EYP001a in Healthy Male Subjects". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03110276. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*